Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
Authors
Keywords
Cancer vaccines, Melanoma, Cyclophosphamide, Regulatory T cells
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 64, Issue 4, Pages 507-518
Publisher
Springer Nature
Online
2015-02-06
DOI
10.1007/s00262-015-1656-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
- (2012) X. Yao et al. BLOOD
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis
- (2012) Benjamin Weide et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of tumoricidal function in CD4+T cells is associated with concomitant memory and terminally differentiated phenotype
- (2012) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cyclophosphamide Promotes Chronic Inflammation–Dependent Immunosuppression and Prevents Antitumor Response in Melanoma
- (2012) Alexandra Sevko et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma
- (2012) Lisa M. Ebert et al. PLoS One
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
- (2012) K. Odunsi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™
- (2011) Theo Nicholaou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
- (2011) A. M. Lesokhin et al. CANCER RESEARCH
- Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
- (2011) Mikayel Mkrtichyan et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine
- (2011) Craig L. Slingluff et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
- (2011) Antonella Sistigu et al. Seminars in Immunopathology
- Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs
- (2010) T. Nakahara et al. BLOOD
- Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
- (2010) Isabel Poschke et al. CANCER RESEARCH
- Selective Depletion of CD4+CD25+Foxp3+Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels
- (2010) Jie Zhao et al. CANCER RESEARCH
- Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma
- (2010) K. Klages et al. CANCER RESEARCH
- Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells
- (2010) Lorna Rettig et al. INTERNATIONAL JOURNAL OF CANCER
- Naive tumor-specific CD4+T cells differentiated in vivo eradicate established melanoma
- (2010) Ying Xie et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
- (2010) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
- (2009) S. Wada et al. CANCER RESEARCH
- The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
- (2009) V. Francois et al. CANCER RESEARCH
- Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
- (2009) T. Nicholaou et al. CLINICAL CANCER RESEARCH
- NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- (2009) S. Gnjatic et al. CLINICAL CANCER RESEARCH
- Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood
- (2008) Camilla Jandus et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
- (2008) F. O. Smith et al. CLINICAL CANCER RESEARCH
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Circumvention of regulatory CD4+ T cell activity during cross-priming strongly enhances T cell-mediated immunity
- (2008) Antje Heit et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now